Gynecological cancer

Textbook of Medical Oncology: Fourth Edition

Volumn , Issue , 2009, Pages 106-122

  Banerjee, Susana ^a   Gore, Martin ^b,c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873612835     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (71)

1. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-4.
2. Young RC, Walton LA, Ellenberg SS et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-7.
3. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-12.
4. Swart AC. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). J Clin Oncol (2007 ASCO Annual Meeting Proceedings Part I) 2007; 25: 5509.
5. Bell J, Brady MF, Young RC et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 102: 432-9.
6. Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78: 1479-87.
7. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-9.
8. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-200.
9. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
10. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
11. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-92.
12. Gadducci A, Sartori E, Landoni F et al. Relationship between time interval from primary surgery to the start of taxaneplus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol 2005; 23: 751-8.
13. Isonishi S, Yasuda M, Takahashi F et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol (2008 ASCO Annual Meeting Proceedings) 2008; 26: 5506.
14. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18: 106-15.
15. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505-15.
16. Lambert HE, Rustin GJ, Gregory WM et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997; 8: 327-33.
17. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-5.
18. Conte PF, Favalli G, Gaducci A et al. Final results of After-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT). J Clin Oncol (2007 ASCO Annual Meeting Proceedings Part I) 2007; 25: 5505.
19. De Placido S, Scambia G, Di Vagno G et al. Topotecan compared with no therapy after response to surgery and carbo- platin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004; 22: 2635-42.
20. Pfisterer J, Weber B, Reuss A et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first- line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006; 98: 1036-45.
21. Mobus V, Wandt H, Frickhofen N et al. Phase III trial of highdose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007; 25: 4187-93.
22. Cure H, Battista C, Guastalla JP et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. J Clin Oncol [2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)] 2004; 22: 5006.
23. Verschraegen CF, Sittisomwong T, Kudelka AP et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000; 18: 2733-9.
24. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-91.
25. Bookman MA. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I) 2006; 24: 5002.
26. Scarfone G, Scambia G, Raspagliesi F et al. A multicenter, randomized, phase III study comparing paclitaxel/carbopla- tin (PC) versus topotecan/paclitaxel/carboplatin (TPC) in patients with stage III (residual tumor >1 cm after primary surgery) and IV ovarian cancer (OC). J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I) 2006; 24: 5003.
27. Hou JY, Kelly MG, Yu H et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007; 105: 211-17.
28. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006; 103: 1070-6.
29. Kumar L, Hariprasad R, Kumar S et al. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): a prospective randomized study-Interim results. J Cli Oncol (2007 ASCO Annual Meeting Proceedings Part I) 2007; 25: 5531.
30. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332: 629-34.
31. Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004; 351: 2489-97.
32. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
33. Markman M, Markman J, Webster K et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22: 3120-5.
34. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-106.
35. Alberts DS, Liu PY, Wilczynski SP et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008; 108: 90-4.
36. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-707.
37. Gore M, ten Bokkel Huinink W, Carmichael J et al. Clinical evidence for topotecan-paclitaxel noncross-resistance in ovarian cancer. J Clin Oncol 2001; 19: 1893-900.
38. Rose PG, Blessing JA, Mayer AR et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-10.
39. 2) in platinum and paclitaxel- resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101: 436-40.
40. Williams C. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2001; 1: CD001034.
41. Smyth JF, Gourley C, Walker G et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007; 13: 3617-22.
42. Harter P, Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13: 1702-10.
43. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-71.
44. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-6.
45. Yap T, Boss D, Fong PC et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP- ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J Clin Oncol (2007 ASCO Annual Meeting Proceedings Part I) 2007; 25: 3529.
46. Berek JS, Taylor PT, Gordon A et al. Randomized, placebo- controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004; 22: 3507-16.
47. Bower M, Fife K, Holden L et al. Chemotherapy for ovarian germ cell tumours. Eur J Cancer 1996; 32A: 593-7.
48. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24: 4783-91.
49. Kitchener H. ASTEC-A Study in the Treatment of Endometrial Cancer: a randomised trial of lymphadenectomy in the treatment of endometrial cancer. 37th Annual Meeting of the Society of Gynecologic Oncologists (SGO). Gynecol Oncol 2006; 101: S21-2.
50. Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355: 1404-11.
51. Randall ME, Filiaci VL, Muss H et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24: 36-44.
52. Thigpen JT, Brady MF, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736-44.
53. Whitney CW, Brunetto VL, Zaino RJ et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 4-9.
54. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 2159-66.
55. Lissoni A, Zanetta G, Losa G et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996; 7: 861-3.
56. Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
57. Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
58. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8.
59. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
60. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-8.
61. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
62. Peters WA 3rd, Liu PY, Barrett RJ 2nd et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606-13.
63. Landoni F, Maneo A, Colombo A et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350: 535-40.
64. Green J, Kirwan J, Tierney J et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005; CD002225.
65. Kim YS, Shin SS, Nam JH et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol 2008; 108: 195-200.
66. Monk BJ, Huang HQ, Cella D et al. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4617-25.
67. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144-53.
68. Wright JD, Viviano D, Powell MA et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 2006; 103: 489-93.
69. Tran PT, Su Z, Lee P et al. Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol 2007; 105: 641-9.
70. Parthasarathy A, Cheung MK, Osann K et al. The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol 2006; 103: 1095-9.
71. Olawaiye A, Lee LM, Krasner C et al. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol 2007; 106: 628-30.